Why is TG Therapeutics stock sliding today?
Investing.com reports TG Therapeutics (TGTX) shares fell about 4.7% pre-open to $49.60 after its Q2 2026 results. The company said revenue was $240.3M versus ~$228.85M expected, and it raised FY2026 global revenue to about $950M and Briumvi U.S. net product revenue guidance to $890M-$905M. Despite beats, the market had priced in strong growth.
How this was made
The 30-second read
Why it matters
Traders may treat the earnings call as the key near-term information event to validate whether Briumvi commercial momentum can sustain the raised targets and how subcutaneous Phase 3 timing affects future revenue visibility.
Market read
Despite a revenue beat and guidance raise, the stock sells off, suggesting expectations and valuation are the dominant driver into the call.
What to watch
The article cites a wide analyst price-target divergence and a bearish Bank of America stance, which may amplify volatility around any guidance nuance rather than the headline raise itself.
Background
The piece frames TGTX’s pre-open drop as a reaction to Q2 2026 results that were strong on paper (revenue beat, guidance raise) but met elevated expectations.
Ticker impact
TG Therapeutics shares fell 4.7% pre-open after Q2 2026 results beat revenue and raised guidance, but the market had priced in strength.
Choppy to lower open risk, with focus shifting to the 8:30 AM ET earnings call commentary on the U.S. Briumvi run-rate and subcutaneous Phase 3 timeline.
The article attributes the decline to a sell-the-news dynamic versus elevated pre-report expectations, and highlights upcoming call details as the next catalyst.
Market effects
Limited immediate read-through to MS competitors since the article says no material competitor news drove sympathy moves.
None indicated; broader U.S. indices are up while TGTX is down, suggesting company-specific pressure.
None indicated beyond the mention of oil and geopolitics in the headline.
Counterpoint
The sell-the-news move could reverse if management’s call provides additional detail that de-risks the valuation gap (run-rate trajectory or Phase 3 milestones).
Key entities
- companyTG Therapeutics
Subject of the article, with pre-open weakness tied to Q2 results and raised 2026 guidance for Briumvi.
- productBriumvi
TG Therapeutics’ multiple sclerosis therapy referenced for U.S. net product revenue guidance and Phase 3 subcutaneous data timing.
- analyst_firmBank of America
Maintained an Underperform stance with a $20 price target, cited as a persistent drag.
